Deepening our understanding of psychedelics by expanding psychedelic data collection in the United States National Survey on Drug Use and Health

Author:

Barnett Brian S12ORCID

Affiliation:

1. Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA

2. Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, OH, USA

Abstract

Amid a reappraisal of the medicinal and societal worth of psychedelics in many countries, regulatory and financial barriers to conducting clinical research with these compounds appear to be receding. Still, there remains a strong need for a clearer understanding of naturalistic psychedelic use and its associated epidemiology, since this type of psychedelic use, which is growing in many places, will almost certainly always exceed clinical use. Furthermore, psychedelics behave differently depending on the settings in which they are used, meaning many research findings on their effects may significantly differ depending on the contexts in which they are observed. Therefore, improving the collection of data on real-world psychedelic use should be of higher priority for the public health community. Expanding data collection on psychedelic use in the United States National Survey on Drug Use and Health, an already vital tool for researchers examining naturalistic psychedelic use, could address this important public health need, helping ensure the general public, the scientific community, and regulators have access to high-quality information as peoples across the world reevaluate what psychedelics’ place in medicine and society should be.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Psychiatry and Mental health,Pharmacology

Reference23 articles.

1. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006–2020

2. British Broadcasting Corporation (2022) Canada trials decriminalising cocaine, MDMA and other drugs. BBC News, 1 June. London: British Broadcasting Corporation. Available at: https://www.bbc.com/news/world-us-canada-61657095 (accessed 2 June 2022).

3. Campbell D (2022) Demand grows for UK ministers to reclassify psilocybin for medical research. The Guardian, 7 March. London: Guardian Media Group. Available at: https://www.theguardian.com/science/2022/mar/08/demand-grows-for-uk-ministers-to-reclassify-psilocybin-for-medical-research (accessed 2 June 2022).

4. Global Drug Survey (2022) Survey composition. Available at: https://www.globaldrugsurvey.com/gds-surveys/survey-composition/ (accessed 2 June 2022).

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3